Dianzani C, Colangelo D, Tonso E, Guidotto S, Viano I
Institute of Pharmacology and Pharmacognosy, Faculty of Pharmacy, University of Turin, Italy.
Arzneimittelforschung. 1994 Dec;44(12A):1431-3.
The effect of pretreatment with pidotimod ((R)-3-[(S)- (5-oxo-2-pyrrolidinyl)-carbonyl]-thiazolidine-4-carboxylic acid, PGT/1A, CAS 121808-62-6) was evaluated in mice infected with two challenging doses of three different viruses. Mengovirus, Herpes simplex, influenza virus were used. The mice were treated 15 days before the virus challenge. The antiviral effect of pidotimod was evaluated as difference in survival time versus control groups challenged with viruses but not pretreated with pidotimod. In groups pretreated and challenged with the lower dose of each virus strain a statistically significant increase in survival time was observed. On the basis of the known effects of pidotimod on immune system, this effect is due to an immunostimulating effect of this drug.
在感染三种不同病毒的两种挑战性剂量的小鼠中评估了匹多莫德（(R)-3-[(S)-(5-氧代-2-吡咯烷基)-羰基]-噻唑烷-4-羧酸，PGT/1A，CAS 121808-62-6）预处理的效果。使用了脑心肌炎病毒、单纯疱疹病毒、流感病毒。在病毒攻击前15天对小鼠进行治疗。将匹多莫德的抗病毒效果评估为与用病毒攻击但未用匹多莫德预处理的对照组相比存活时间的差异。在用每种病毒株的较低剂量进行预处理和攻击的组中，观察到存活时间有统计学上的显著增加。基于匹多莫德对免疫系统的已知作用，这种效果归因于该药物的免疫刺激作用。
